<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-945
Date of Submission: 2024-11-23

This report was submitted by a Other Healthcare Professional from Mendez-Warren Medical Center concerning patient ANON-PX-2268. The subject is a 42-year-old male with a significant medical history including atrial fibrillation, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intramuscular route at a dosage of 448mg, initiated on 2024-10-22 for Neuropathic pain and discontinued on 2024-11-09.

On approximately 2024-11-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Dizziness, Headache, Pruritus. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed need and advised itself. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-945
report_date: '2024-11-23'
patient_details:
  patient_id: ANON-PX-2268
  gender: Male
  relevant_history:
  - atrial fibrillation
  - hypertension
  age_at_reaction: 42
suspected_drugs:
- drug_name: Gabapentin
  dosage: 448mg
  route_of_administration: Intramuscular
  start_date: '2024-10-22'
  indication_for_use: Neuropathic pain
  end_date: '2024-11-09'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-11-09'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2024-11-09'
  severity: Mild
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed need and advised itself.
- symptom_name: Headache
  onset_date: '2024-11-09'
  severity: Severe
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2024-11-09'
  severity: Moderate
  outcome: Recovering
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Mendez-Warren Medical Center
reporter_type: Other Healthcare Professional
